(Date:12/4/2008)...Newswire/ -- Joe,s Sports & Outdoor stores,ac...0 during the months of,August and September for t...hird consecutive year, Joe,s provided shoppers the...erosity by donating to CCA at checkout stands in a...llis, said, "Once again, we are pleased to,receiv...
(Date:12/4/2008)...ewswire/ -- STINSON Brand Innovation, Inc.,announ...th MarCom and Davey,Awards for work done for its ...The honors include two MarCom awards and six Davey...cian ads to logo design. , , Specifically, ...oscience Logo Design (Gold), -- CSL Behring, ...
(Date:12/4/2008)...ersary of drive to eliminate lymphatic filariasis ...blet and grant to The Carter Center , , LON.../ -- In a meeting today with former U.S. President...s well as global health thought leaders from aroun...nounced that it has made a $250,000 donation to Th...
(Date:12/4/2008)...Carraguard had no decrease in infections, trial fo...) -- A microbicidal vaginal gel called Carraguard ...t,s the conclusion of a study that included more t...hree sites in South Africa. , The women were gi... use one applicator of gel and a condom each time ...
Breaking Medicine News(10 mins):Health News:Joe's Sports & Outdoor In-Store Promotion Raises $18,000 for the Children's Cancer Association 2Health News:STINSON Brand Innovation, Inc. Recognized With 8 Creative Awards 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Experimental Vaginal Gel Doesn't Ward Off HIV 2... with Down's Syndrome was denied an account at a b...she was 'mentally incompetent'. Charlotte and her...reatment meted out to them from the Barclays bank ...er the staff declared that the bank policies made ...
...r. Honglei Chen, of the National Institutes of Hea...may result in Parkinson’s disease//. The study was.... It said that those who work in the rotating nigh... the disease. This is because the author says tha...
...un offering "bloodless surgery" to almost 90% of i...al now joins an ever-growing number of hospitals t...icine around the country. This option was once on...ut is now provided in certain hospitals to more pa...
...rin when taken along with gentamycin can prevent t... The results of the study are especially importan...osides family of antibiotics, which includes genta...their low cost and ready availability. The study ...
Other Medicine News:Health News:Aspirin to Prevent Deafness caused by Antibiotics 2(Date:12/4/2008)...if., Dec. 4 ISTA Pharmac...armaceutical company, today announced results from...al program of Xibrom(TM) (0.09% bromfenac sodium o...enrolled 282 patients who underwent cataract surge...sked, parallel-group, vehicle-controlled studies t...
(Date:12/4/2008)... Calif., Dec. 4 Thoratec... device-based mechanical circulatory support,ther... said today that a,pre-specified interim analysis...y (DT) pivotal trial shows that patients implanted...outcomes versus those in the control group who,we...
(Date:12/4/2008)... Calif., Dec. 4 Long-term data pub...ed decrease in Mitral Vale Area (MVA),after repai...egurgitation (MR),is not associated with clinical...h two years of follow-up, none of the patients tre...y for mitral stenosis. At 12 months no,important ...
(Date:12/4/2008)...December 4 Biopharmaceutical compa...essfully completed treatment of the,last patient ...), a donor,lymphocyte cell based product, is unde...Disease (GvHD) and allow early immune reconstituti...tion. Nineteen end stage blood cancer,patients we...
Breaking Medicine Technology:ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09% 2ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09% 3ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09% 4Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 2Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 3Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 4Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations 2CYNACON OCuSOFT 28OCuSOFT Inc 29 Names Katherine M Mastrota M S O D to Medical Scientific Advisory Board 2692 1Stars Shine on Butterflies Over Hollywood for Lupus Foundation of America 2688 1Stars Shine on Butterflies Over Hollywood for Lupus Foundation of America 2688 2ADA Updates Environmental Recommendations for Handling Waste 2686 1ADA Updates Environmental Recommendations for Handling Waste 2686 2Congressional Support Grows for FDA Regulation of Tobacco 3A Bill Now Sponsored by 55 Senators 200 Representatives 2682 1Congressional Support Grows for FDA Regulation of Tobacco 3A Bill Now Sponsored by 55 Senators 200 Representatives 2682 2... report no new stent thrombosis after two years in...BARCELONA, Spain, May 22, 2007,/PRNewswire-FirstCa...ed four-year follow-up data from its TAXUS VI clin...and efficacy benefits,associated with a moderate-r...litaxel-eluting stent system -- which is not,appro...
...ain--(BUSINESS WIRE)--May 22, 2007 - Medtronic,(NY...e ENDEAVOR,clinical trial program reinforcing the ...or(R) drug-eluting coronary stent system.,Four-yea...OR I,trial and three-year results from the nearly ...ndeavor is associated with sustained,safety, signi...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 2Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 3Aaron manufactures two groups of flexible lighting products. The first is available both sterile and non-sterile in three different sizes 5", 10", and 15" (refers to the flexible shaft portion of the
...maintains power to the instrument without generati...s of 50 Hz separated by .75 s; repeats every 10 s ...tanus: 50 Hz (50 pulses/s) or 100 Hz (100 pulses/s...s , Output Current: Adjustable from 0-70 mA (HI ra...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte
Based on the original MS-III design the new MS-IV includes electrosurgery certification, enhanced keypad and battery compartment designs., ,The MiniStim® MS-IV peripheral nerve stimulator can
Medicine Products: